Two trials, two approved groups
The heart evidence for semaglutide comes from two landmark trials covering different people. Getting them straight is the key to understanding what applies to you.
Ozempic in type 2 diabetes — SUSTAIN-6
SUSTAIN-6 (NEJM, 2016) studied 3,297 adults with type 2 diabetes at high cardiovascular risk. Semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 26%versus placebo (hazard ratio 0.74). This is the basis for Ozempic's FDA cardiovascular indication in diabetes.
Wegovy in obesity without diabetes — SELECT
SELECT (NEJM, 2023) studied 17,604 adults with established heart disease and overweight/obesity but not diabetes. Over ~3.3 years, semaglutide 2.4 mg cut major cardiovascular events to 6.5% vs 8.0% on placebo — a 20% reduction (HR 0.80). This led the FDA to approve Wegovy for cardiovascular risk reduction in March 2024 — the first weight-loss drug with such an approval. Full context in our Ozempic safety overview.
How does it protect the heart?
The exact mechanisms are still being worked out and are probably several at once — weight loss, better blood-sugar control, lower blood pressure, reduced inflammation, and direct effects on blood vessels. A striking finding in SELECT was that the cardiovascular benefit appeared earlier and larger than the weight loss alone would explain — which suggests semaglutide does more for the heart than simply helping people lose weight.
What this does — and doesn't — mean for you
If you have type 2 diabetes with heart disease, or established heart disease with overweight/obesity, this is real, on-label evidence worth discussing with your clinician. It does not mean semaglutide replaces statins, blood-pressure medicines, or other proven cardiac care — it is an addition to them, for the right patients. And it is not a reason to start the drug on your own; these are prescription medications with real risks.
How to read a “20% risk reduction”
This is the number most often quoted and least often explained. A percentage like that is a relative risk reduction — it describes how much the event rate fell compared with the comparison group, not your personal chance of anything.
The distinction matters because the same relative figure means very different things depending on your baseline risk. A 20% reduction applied to a high underlying risk removes a substantial number of events; applied to a low underlying risk it removes very few. That is precisely why the approved population is defined the way it is — established cardiovascular disease — rather than extended to everyone. The people in the trials already had meaningful risk, which is what made a relative reduction worth having.
So the useful question for your own appointment is not “how big is the percentage?” but “given my risk, what does this change for me?” Your clinician can answer that with your actual history in front of them. Anyone quoting the headline figure as though it applied identically to everyone is misreading it.
Why this indication matters for coverage
There is a practical consequence that has nothing to do with cardiology. A cardiovascular-risk indication is not a weight-loss indication — which means coverage can be available through it even when a plan excludes weight-loss drugs entirely.
Employer plans that carve out weight-loss medication are common, and people in that situation often conclude they have no route at all. If you have established cardiovascular disease alongside overweight or obesity, that conclusion may be wrong: the request would be made on the cardiovascular indication, documented as such. What that takes in practice:
- A documented cardiovascular diagnosis in your chart, with the relevant history — not a general statement of risk factors.
- The right product, since the indication belongs to a specific approved product rather than to the molecule generally.
- A prior authorization filed on that indication — see the PA criteria.
- An appeal route if denied — see appealing a GLP-1 denial.
Whether it applies to you depends on your documented diagnosis and your specific plan language. This is a question to put to your prescriber and your plan, not a guarantee.
What to ask your cardiologist or prescriber
- Given my history, do I fall within the approved population for this indication?
- What does the risk reduction mean for someone with my baseline risk?
- How does this sit alongside my statin, blood-pressure medication, and anything else I take for my heart?
- If my plan excludes weight-loss drugs, would we file on the cardiovascular indication instead?
- What would we monitor, and what would make us stop?
This page is educational, dated 2026-07-18, and not medical advice. Whether a GLP-1 fits your cardiovascular care is a decision for your cardiologist or prescriber.